MY SITE
  • Home
  • General Information
    • Welcome
    • Top 10 Reasons to Attend
    • 2021 Program Committee
    • Board of Directors
    • Contact CRS
    • Code of Conduct
  • Program, Abstracts, & Speakers
    • Conference Program >
      • Tech Forums
      • Workshops
    • Invited Speakers
    • Abstract Submissions
    • Special Groups >
      • Consumer & Diversified Products Division
      • Women in Science
      • Young Scientist Committee
  • Industry Involvment
    • Exhibit & Sponsor Pricing
    • Workshops
    • 2021 Sponsors & Exhibitors
    • Corporate Membership
  • On-Demand Pricing

The Constantly-Evolving Microparticulate: Applications and Advances

Monday, July 26th - 12pm (Noon) EDT  
Sponsored By:
Picture
​Microsphere manufacturing techniques have been used in pharmaceutical applications for decades: the dose and format flexibility associated with microparticulates makes them a “go-to” option for drug product intermediate formulations.  A timeless tripartite conflict exists within the microparticulate space, however: the balance of small particle size, high particle uniformity, and controlled release rate.  Specifically, formulators oftentimes cannot achieve all three simultaneously.  Because these challenges exist within both the solid oral and injectable space, there has been considerable effort on behalf of many organizations to align small size, high uniformity, and maintenance of controlled release.  This presentation covers the advantages of microparticulates, the types of manufacturing used in solid oral and injectable applications, and the latest contributions from organizations to create a new “gold standard.”
Speaker
Dr. Nathan Dormer​
Adare Pharma Solutions, Director of Drug Product Development 
Picture
​Dr. Dormer is a pharmaceutical scientist and bioengineer with over a decade of experience developing microsphere-based solid oral and parenteral/implantable dosage forms, with an emphasis on controlled release and other innovative formulation concepts. He is responsible for pharmaceutical development activities such as creation of prototypes, analytical method development, CMC and IP documentation, pharmacokinetic correlations, tech transfer, manufacture of clinical supplies, and commercial scale process optimization and validation. Dr. Dormer received his B.S. in Chemical Engineering and his Ph.D. with Honors in Bioengineering, both from The University of Kansas.

Powered by Create your own unique website with customizable templates.
  • Home
  • General Information
    • Welcome
    • Top 10 Reasons to Attend
    • 2021 Program Committee
    • Board of Directors
    • Contact CRS
    • Code of Conduct
  • Program, Abstracts, & Speakers
    • Conference Program >
      • Tech Forums
      • Workshops
    • Invited Speakers
    • Abstract Submissions
    • Special Groups >
      • Consumer & Diversified Products Division
      • Women in Science
      • Young Scientist Committee
  • Industry Involvment
    • Exhibit & Sponsor Pricing
    • Workshops
    • 2021 Sponsors & Exhibitors
    • Corporate Membership
  • On-Demand Pricing